Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Zelenetz, Andrew D., Salles, Gilles, Mason, Kylie D., Casulo, Carla, Le Gouill, Steven, Sehn, Laurie H., Tilly, Herve, Cartron, Guillaume, Chamuleau, Martine E. D., Goy, Andre, Tam, Constantine S., Lugtenburg, Pieternella J., Petrich, Adam M., Sinha, Arijit, Samineni, Divya, Herter, Sylvia, Ingalla, Ellen, Szafer-Glusman, Edith, Klein, Christian, Sampath, Deepak, Kornacker, Martin, Mobasher, Mehrdad, Morschhauser, Franck
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2019
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497517/
https://ncbi.nlm.nih.gov/pubmed/30850381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-11-880526
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky